Zydus Lifesciences has announced the successful conclusion of a GMP surveillance inspection conducted by the USFDA at its Unit 9 facility in Ahmedabad. The inspection, held from April 27 to May 5, 2026, resulted in seven observations. The company confirmed that there were no data integrity issues identified during the process. Management has committed to working closely with the regulatory agency to address these findings promptly.
Inspection Overview
Zydus Lifesciences successfully concluded a USFDA Good Manufacturing Practice (GMP) surveillance inspection at its Biologics Injectable plant, designated as Unit 9, located at Zydus Biotech Park in Changodar, Ahmedabad. The assessment took place over a period of nine days, running from April 27, 2026, through May 5, 2026.
Key Findings and Next Steps
Following the conclusion of the onsite visit, the USFDA issued seven observations regarding the facility’s operations. Notably, the company highlighted that there were no observations related to data integrity, which serves as a positive indicator of the company’s quality control systems. Zydus Lifesciences has expressed its commitment to addressing these observations in a timely and comprehensive manner to ensure full alignment with regulatory expectations.
Source: BSE
